Posted by Michael Wonder on 04 May 2022
Graphite Bio announces U.S. FDA fast track designation granted to GPH101 for the treatment of sickle cell disease
3 May 2022 - GPH101 is an investigational next-generation gene-edited therapy designed to potentially provide a one time cure for patients.
Graphite Bio today announced that the U.S. FDA has granted fast track designation to GPH101 for the treatment of sickle cell disease.
